Paclitaxel-coated balloons in refractory nonanastomostic airway stenosis following lung transplantation

Am J Transplant. 2014 Oct;14(10):2400-5. doi: 10.1111/ajt.12845. Epub 2014 Jul 23.

Abstract

Airway stenosis represents the commonest airway complication following lung transplantation, affecting between 7% and 18% of patients. Existing treatment options offer limited efficacy and can cause additional patient morbidity. Paclitaxel-coated balloons (PCB) have proved effective in managing postinterventional coronary artery re-stenosis. In a first-in-man study, we evaluated similar PCBs in refractory nonanastomotic airway stenosis in 12 patients. Following a single application, luminal patency was maintained in 50% at 270 days. No significant peri-interventional or early postinterventional complications occurred. Given these encouraging initial findings, further studies appear warranted.

Keywords: Clinical research/practice; comorbidities; complication; lung (allograft) function/dysfunction; lung transplantation/pulmonology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Bronchi / physiopathology*
  • Constriction, Pathologic / therapy*
  • Female
  • Humans
  • Lung Transplantation*
  • Male
  • Middle Aged
  • Paclitaxel / administration & dosage*

Substances

  • Antineoplastic Agents, Phytogenic
  • Paclitaxel